Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Y-Mabs Therapeutics ( (YMAB) ) has issued an announcement.
On July 11, 2025, Y-mAbs Therapeutics held its annual meeting of stockholders where three key proposals were voted on. The stockholders elected David N. Gill as a Class I director until 2028, ratified PricewaterhouseCoopers LLP as the independent accounting firm for 2025, and approved the executive compensation in a non-binding advisory vote. These decisions are significant for the company’s governance and operational oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (YMAB) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Y-Mabs Therapeutics stock, see the YMAB Stock Forecast page.
Spark’s Take on YMAB Stock
According to Spark, TipRanks’ AI Analyst, YMAB is a Neutral.
Y-Mabs Therapeutics faces significant challenges with profitability and cash flow despite revenue growth. The technical analysis indicates a bearish trend, and the valuation is not compelling due to negative earnings. While the earnings call presented some positive developments, the strategic realignment must address key challenges to improve the outlook.
To see Spark’s full report on YMAB stock, click here.
More about Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel antibody-based products for the treatment of cancer. The company primarily targets pediatric oncology and rare diseases, aiming to address unmet medical needs in these areas.
Average Trading Volume: 202,383
Technical Sentiment Signal: Sell
Current Market Cap: $197.5M
See more insights into YMAB stock on TipRanks’ Stock Analysis page.